Cargando…
Vedolizumab and early postoperative complications in nonintestinal surgery: a case-matched analysis
BACKGROUND: Vedolizumab (VDZ) is a gut-specific α4-β7 integrin antagonist that has demonstrated efficacy in Crohn’s disease (CD) and ulcerative colitis (UC). The safety of VDZ in the perioperative period remains unclear. The aim of this study was to evaluate postoperative complications and periopera...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6024272/ https://www.ncbi.nlm.nih.gov/pubmed/29977340 http://dx.doi.org/10.1177/1756284818783614 |
_version_ | 1783336026460127232 |
---|---|
author | Kotze, Paulo Gustavo Ma, Christopher Mckenna, Nicholas Almutairdi, Abdulelah Kaplan, Gilaad G. Raffals, Laura E. Loftus, Edward V. Panaccione, Remo Lightner, Amy L. |
author_facet | Kotze, Paulo Gustavo Ma, Christopher Mckenna, Nicholas Almutairdi, Abdulelah Kaplan, Gilaad G. Raffals, Laura E. Loftus, Edward V. Panaccione, Remo Lightner, Amy L. |
author_sort | Kotze, Paulo Gustavo |
collection | PubMed |
description | BACKGROUND: Vedolizumab (VDZ) is a gut-specific α4-β7 integrin antagonist that has demonstrated efficacy in Crohn’s disease (CD) and ulcerative colitis (UC). The safety of VDZ in the perioperative period remains unclear. The aim of this study was to evaluate postoperative complications and perioperative safety in VDZ-treated patients undergoing nonintestinal operations. METHODS: A case-matched study was performed at two inflammatory bowel disease (IBD) referral centers. Adult patients with CD and UC who underwent a nonintestinal surgical procedure during treatment with VDZ were included. Patients who had their last VDZ infusion up to 12 weeks before the procedure were considered exposed and were matched in a 1:1 ratio to patients without VDZ therapy, according to type of surgical procedure, age, and sex. The primary outcome was overall risk of early postoperative infectious complications (up to 30 days after surgery), readmissions, reoperations, surgical site infections, and other infections. The VDZ and control groups were subsequently compared using the Pearson χ(2) test and Wilcoxon rank sum. RESULTS: We identified 34 patients treated with VDZ who underwent 36 nonintestinal surgical procedures. These patients were matched with 36 control procedures. Postoperative complications were not different between the VDZ-treated and control cohorts for all outcomes analyzed: infectious complications occurred in 14% versus 8% (p = 0.45), superficial surgical site infections 6% versus 0% (p = 0.15), reoperations 6% versus 3% (p = 0.56) and readmissions 11% versus 6% (p = 0.37). CONCLUSIONS: VDZ-treated patients with IBD undergoing nonintestinal procedures did not have an increased risk of overall postoperative infections or other complications compared with matched controls. |
format | Online Article Text |
id | pubmed-6024272 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | SAGE Publications |
record_format | MEDLINE/PubMed |
spelling | pubmed-60242722018-07-05 Vedolizumab and early postoperative complications in nonintestinal surgery: a case-matched analysis Kotze, Paulo Gustavo Ma, Christopher Mckenna, Nicholas Almutairdi, Abdulelah Kaplan, Gilaad G. Raffals, Laura E. Loftus, Edward V. Panaccione, Remo Lightner, Amy L. Therap Adv Gastroenterol Original Research BACKGROUND: Vedolizumab (VDZ) is a gut-specific α4-β7 integrin antagonist that has demonstrated efficacy in Crohn’s disease (CD) and ulcerative colitis (UC). The safety of VDZ in the perioperative period remains unclear. The aim of this study was to evaluate postoperative complications and perioperative safety in VDZ-treated patients undergoing nonintestinal operations. METHODS: A case-matched study was performed at two inflammatory bowel disease (IBD) referral centers. Adult patients with CD and UC who underwent a nonintestinal surgical procedure during treatment with VDZ were included. Patients who had their last VDZ infusion up to 12 weeks before the procedure were considered exposed and were matched in a 1:1 ratio to patients without VDZ therapy, according to type of surgical procedure, age, and sex. The primary outcome was overall risk of early postoperative infectious complications (up to 30 days after surgery), readmissions, reoperations, surgical site infections, and other infections. The VDZ and control groups were subsequently compared using the Pearson χ(2) test and Wilcoxon rank sum. RESULTS: We identified 34 patients treated with VDZ who underwent 36 nonintestinal surgical procedures. These patients were matched with 36 control procedures. Postoperative complications were not different between the VDZ-treated and control cohorts for all outcomes analyzed: infectious complications occurred in 14% versus 8% (p = 0.45), superficial surgical site infections 6% versus 0% (p = 0.15), reoperations 6% versus 3% (p = 0.56) and readmissions 11% versus 6% (p = 0.37). CONCLUSIONS: VDZ-treated patients with IBD undergoing nonintestinal procedures did not have an increased risk of overall postoperative infections or other complications compared with matched controls. SAGE Publications 2018-06-21 /pmc/articles/PMC6024272/ /pubmed/29977340 http://dx.doi.org/10.1177/1756284818783614 Text en © The Author(s), 2018 http://www.creativecommons.org/licenses/by-nc/4.0/ This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (http://www.creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage). |
spellingShingle | Original Research Kotze, Paulo Gustavo Ma, Christopher Mckenna, Nicholas Almutairdi, Abdulelah Kaplan, Gilaad G. Raffals, Laura E. Loftus, Edward V. Panaccione, Remo Lightner, Amy L. Vedolizumab and early postoperative complications in nonintestinal surgery: a case-matched analysis |
title | Vedolizumab and early postoperative complications in nonintestinal surgery: a case-matched analysis |
title_full | Vedolizumab and early postoperative complications in nonintestinal surgery: a case-matched analysis |
title_fullStr | Vedolizumab and early postoperative complications in nonintestinal surgery: a case-matched analysis |
title_full_unstemmed | Vedolizumab and early postoperative complications in nonintestinal surgery: a case-matched analysis |
title_short | Vedolizumab and early postoperative complications in nonintestinal surgery: a case-matched analysis |
title_sort | vedolizumab and early postoperative complications in nonintestinal surgery: a case-matched analysis |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6024272/ https://www.ncbi.nlm.nih.gov/pubmed/29977340 http://dx.doi.org/10.1177/1756284818783614 |
work_keys_str_mv | AT kotzepaulogustavo vedolizumabandearlypostoperativecomplicationsinnonintestinalsurgeryacasematchedanalysis AT machristopher vedolizumabandearlypostoperativecomplicationsinnonintestinalsurgeryacasematchedanalysis AT mckennanicholas vedolizumabandearlypostoperativecomplicationsinnonintestinalsurgeryacasematchedanalysis AT almutairdiabdulelah vedolizumabandearlypostoperativecomplicationsinnonintestinalsurgeryacasematchedanalysis AT kaplangilaadg vedolizumabandearlypostoperativecomplicationsinnonintestinalsurgeryacasematchedanalysis AT raffalslaurae vedolizumabandearlypostoperativecomplicationsinnonintestinalsurgeryacasematchedanalysis AT loftusedwardv vedolizumabandearlypostoperativecomplicationsinnonintestinalsurgeryacasematchedanalysis AT panaccioneremo vedolizumabandearlypostoperativecomplicationsinnonintestinalsurgeryacasematchedanalysis AT lightneramyl vedolizumabandearlypostoperativecomplicationsinnonintestinalsurgeryacasematchedanalysis |